Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -34 Million USD | 70.58% |
| 2022 | -115.59 Million USD | -92.7% |
| 2021 | -59.98 Million USD | -52.11% |
| 2020 | -39.43 Million USD | -86.53% |
| 2019 | -21.14 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.1 Million USD | -18.3% |
| 2024 Q1 | -5.16 Million USD | -10.32% |
| 2023 Q3 | -3.78 Million USD | 61.73% |
| 2023 FY | -34 Million USD | 70.58% |
| 2023 Q4 | -4.68 Million USD | -23.8% |
| 2023 Q2 | -9.88 Million USD | -133.14% |
| 2023 Q1 | 29.81 Million USD | 207.42% |
| 2022 Q2 | -22.62 Million USD | 7.94% |
| 2022 Q1 | -24.58 Million USD | -28.95% |
| 2022 FY | -115.59 Million USD | -92.7% |
| 2022 Q4 | -27.75 Million USD | 31.7% |
| 2022 Q3 | -40.63 Million USD | -79.56% |
| 2021 FY | -59.98 Million USD | -52.11% |
| 2021 Q4 | -19.06 Million USD | -91.91% |
| 2021 Q3 | -9.93 Million USD | 41.63% |
| 2021 Q1 | -13.97 Million USD | -6.41% |
| 2021 Q2 | -17.01 Million USD | -21.77% |
| 2020 FY | -39.43 Million USD | -86.53% |
| 2020 Q4 | -13.13 Million USD | -30.26% |
| 2020 Q3 | -10.08 Million USD | -20.59% |
| 2020 Q2 | -8.36 Million USD | -6.32% |
| 2020 Q1 | -7.86 Million USD | 0.0% |
| 2019 FY | -21.14 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -6801.941% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -257.239% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -13.366% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 49.359% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -114.618% |
| Better Therapeutics, Inc. | -38.26 Million USD | 11.134% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 19.185% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -184.06% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -0.467% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 1.212% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 68.652% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1588.029% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 27.58% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2386.642% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -70.528% |
| Molecular Templates, Inc. | -10.46 Million USD | -224.881% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -141.992% |
| NexImmune, Inc. | -29.19 Million USD | -16.475% |
| Orgenesis Inc. | -53.63 Million USD | 36.606% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 33.712% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -43482.809% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -110.6% |
| Scopus BioPharma Inc. | -11.71 Million USD | -190.246% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 93.258% |
| Statera Biopharma, Inc. | -98.34 Million USD | 65.425% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -392.925% |
| Trevena, Inc. | -35.28 Million USD | 3.644% |
| Vaxxinity, Inc. | -58.28 Million USD | 41.663% |
| Vaccinex, Inc. | -22.88 Million USD | -48.578% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3147.633% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 32.926% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -368.153% |